. 2022 Jun 10;17:1365–1379. doi: 10.2147/COPD.S359873

Table 1.

Characteristics of Studies Reporting the Prevalence of COPD-Related PH

Study	Country	Enrolment Time	Total	Gender (M/F)	Mean Age	Sample Source	Sample Type	Diagnostic Methods for PH	Prevalence
Acharya et al 2018⁴⁶	India	2012–2014	50	NA	61.14±10.33	NA	Stable	TTE	54.00%
Aksu et al 2013⁴⁷	Turkey	2008–2009	89	77/12	60.6±8.5	NA	Stable	TTE	23.60%
Alkukhun et al 2014⁴⁸	America	2004–2011	92	31/61	55.1	Lung transplants	NA	RHC	32.60%
Andersen et al 2012¹⁵	Danish	1991–2010	409	140/216	54.01	Lung transplants	Stable	RHC	48.66%
Blanco et al 2019⁴⁹	Spain	NA	3105	1612/1493	59.5	Lung transplants	NA	RHC	54.00%
Buklioska et al 2019⁵⁰	Skopje	2018–2018	60	52/8	NA	NA	NA	TTE	33.33%
Chaouat et al 2009⁵¹	France	NA	183	160/23	67.0–79.0	NA	Stable	TTE	21.90%
Chen et al 2015⁵²	China	2013–2014	221	175/46	69±10	Inpatients		TTE	25.34%
Fayngersh et al 2011⁵³	America	2002–2008	174	155/19	40–80	NA	Stable	TTE	37.36%
Freixa et al 2012⁵⁴	Spain	2004–2006	342	318/24	67.9±8.6	Inpatients	AECOPD	TTE	19.00%
Gartman et al 2012⁵⁵	America	2008–2010	142	84/58	59	Lung transplants	NA	RHC	63.38%
Gupta et al 2018⁵⁶	India	2015–2016	109	72/27	58.04	NA	NA	TTE	62.40%
Halvani et al 2019⁵⁷	Islam	NA	142	NA	67.5–70.8	Outpatients	Stable	TTE	63.38%
Hayes et al 2017⁵⁸	America	2005–2013	86	31/55	60.86	Outpatients	Stable	TTE	63.00%
Hilde et al 2016⁵⁹	Norway	NA	100	49/51	63±7	NA	Stable	RHC	26.00%
Jethani et al 2016⁶⁰	India	NA	50	49/1	35–80	NA	NA	TTE	48.00%
Kwon et al 2010⁶¹	Korea	2009	108	82/26	71.79	NA	NA	TTE	53.70%
Malinovschi et al 2014⁶²	Italy	2011–2012	276	186/90	67.76	Inpatients	Stable	RHC	47.80%
Matsuyama et al 2001⁶³	Japan	NA	65	NA	65.64	Inpatients	NA	RHC	32.31%
Mohamed et al 2016⁶⁴	Netherlands	2004–2014	65	33/32	59.34	Lung transplants	NA	RHC	58.46%
Mohamed et al 2019⁶⁵	Egypt	2017–2018	228	NA	63.30±9.22	Outpatients	Stable	TTE	63.00%
Nakahara et al 2016⁶⁶	Japan	2007–2013	503	NA	69.9±6.8	Inpatients	Stable	RHC	16.70%
Nakayama et al 2020⁶⁷	Japan	2010–2012	105	57/48	68.14	NA	NA	TTE	60.00%
Nathan et al 2012⁶⁸	America	2005–2018	6572	3252/3320	60.4±6.3	Lung transplants	NA	RHC	52.40%
Portillo et al 2015⁶⁹	Spain	NA	139	134/5	63±8	NA	Stable	RHC	18.00%
Sertogullarindan et al 2012⁷⁰	Turkey	2000–2010	600	336/264	67±10	Inpatients	Stable	TTE	54.17%
Seyhan et al 2013⁷¹	Turkey	2007–2009	270	207/63	61±7.3	NA	Stable	TTE	48.00%
Shabrawy et al 2017⁷²	Egypt	2012–2014	252	163/89	58.46	NA	AECOPD	TTE	64.80%
Shin et al 2014⁷³	America	1998–2012	148	118/30	63.39	NA	Stable	RHC	39.00%
Sims et al 2009⁷⁴	America	1991–2003	362	NA	55.95	Lung transplants	NA	RHC	23.00%
Skjorten et al 2013⁷⁵	Norway	2006	96	48/48	63.47	Outpatients	Stable	RHC	26.00%
Sridhara et al 2020⁷⁶	India	NA	106	NA	NA	NA	NA	RHC	16.00%
Stolz et al 2008⁷⁷	Switzerland	NA	123	NA	NA	Inpatients	AECOPD	TTE	22.80%
Sun et al 2019⁷⁹	China	2016–2018	106	97/9	69.5±10.1	NA	Stable	TTE	22.60%
Takahashi et al 2018⁷⁹	Japan	2006–2016	131	NA	NA	NA	NA	TTE	12.98%
Xiong et al 2018⁸⁰	China	2015–2017	97	49/48	67.5±10.5	Lung transplants	Stable	TTE	23.71%
Xiong et al 2020⁸¹	China	NA	513	432/81	68.02	Outpatients	Stable	TTE	29.24%
Yazici et al 2019⁸²	Turkey	2015–2018	126	119/7	66.73±9.76	Outpatients	NA	TTE	26.19%

Abbreviations: AECOPD, acute exacerbation of chronic obstructive pulmonary disease; M/F, the number of males/the number of females; NA, not available or applicable; PH, pulmonary hypertension; TTE, transthoracic echocardiography; RHC, right heart catheterization.